Illumina (ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics enabled on the TruSight Oncology Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina’s commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target lowered to $124 from $126 at RBC Capital
- Cathie Wood Buys Deere Stock (DE) on Post-Earnings Dip, Builds Stakes in Exact Sciences and Robinhood Stocks
- Icahn exits Illumina, Dana; boosts stakes in CVR Energy
- Illumina downgraded to Neutral from Outperform at Daiwa
- Illumina price target raised to $105 from $100 at Morgan Stanley